Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd Sells 6,500 Shares of Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 6,500 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $144.25, for a total transaction of $937,625.00. Following the completion of the transaction, the chief executive officer now owns 464,058 shares in the company, valued at $66,940,366.50. This represents a 1.38 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jazz Pharmaceuticals Trading Down 2.3 %

Shares of NASDAQ JAZZ opened at $140.22 on Tuesday. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $148.06. The company has a market cap of $8.52 billion, a price-to-earnings ratio of 19.75, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock’s 50 day simple moving average is $127.01 and its 200 day simple moving average is $119.37.

Wall Street Analyst Weigh In

JAZZ has been the topic of several recent analyst reports. Needham & Company LLC boosted their price target on Jazz Pharmaceuticals from $205.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th. JPMorgan Chase & Co. upped their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Robert W. Baird raised their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. TD Cowen cut their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Finally, HC Wainwright reissued a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $182.47.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Fuller & Thaler Asset Management Inc. grew its position in shares of Jazz Pharmaceuticals by 117.4% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock worth $115,681,000 after acquiring an additional 507,234 shares during the last quarter. Darwin Global Management Ltd. acquired a new position in Jazz Pharmaceuticals during the 4th quarter valued at about $59,668,000. Dimensional Fund Advisors LP grew its position in Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock worth $250,619,000 after purchasing an additional 320,724 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Jazz Pharmaceuticals by 20.9% in the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after purchasing an additional 315,608 shares during the period. Finally, GMT Capital Corp increased its stake in shares of Jazz Pharmaceuticals by 140.0% in the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock valued at $62,659,000 after purchasing an additional 296,800 shares during the period. 89.14% of the stock is currently owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.